ACT Biotech, Eddingpharm deal

Eddingpharm acquired exclusive, worldwide rights to develop and commercialize oncology compounds telatinib, ACTB1003 and ACTB1010 from ACT Biotech. Eddingpharm said the deal includes "several hundred" compounds from the same family as the three leads. ACT Biotech received an undisclosed upfront payment and is eligible for milestones. Eddingpharm said the deal is valued at up to $95 million, including the upfront payment. ...